Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DAVID ALBERT GREMSE

Allopathic & Osteopathic Physicians Pediatrics Pediatric Gastroenterology

NPI
1750369468
CMS profile
306691
Location
MOBILE, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$174.48

6 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $174.48 6

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
AbbVie Inc. $160.34 5
Nestle HealthCare Nutrition Inc. $14.14 1

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DAVID ALBERT GREMSE

NPI 1750369468 · CMS profile ID 306691

Allopathic & Osteopathic Physicians / Pediatrics / Pediatric Gastroenterology

MOBILE, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1750369468?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DAVID ALBERT GREMSE, NPI 1750369468, CMS profile ID 306691. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1750369468?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). DAVID ALBERT GREMSE, NPI 1750369468, CMS profile ID 306691. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1750369468?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
DAVID ALBERT GREMSE, NPI 1750369468, CMS profile ID 306691, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1750369468?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

6 matching records · $174.48 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 6 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–6 of 6.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AbbVie Inc. $15.4710/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794670739 CMS
AbbVie Inc. $104.0009/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794670737 CMS
AbbVie Inc. $4.7309/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794670733 CMS
AbbVie Inc. $16.7108/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794670729 CMS
Nestle HealthCare Nutrition Inc. $14.1407/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820901131 CMS
AbbVie Inc. $19.4303/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794670725 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2021 $174.48 6
PY2022 $374.29 14
PY2023 $271.66 12
PY2024 $1,739.94 20
PY2025 $376.03 8

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $198,587.61 104
PY2024 Principal investigator $217,659.62 148
PY2023 Principal investigator $97,220.00 54
PY2022 Principal investigator $32,000.00 10
PY2021 Recipient $6,500.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

148 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,500.00 12/18/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1125482264
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $104.00 12/18/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1125482266
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $273.00 12/18/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1125482268
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,851.00 12/18/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1125482270
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $554.00 12/18/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1125482272
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $82.00 12/18/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1125482274
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $196.00 12/18/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1125482276
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $60.00 12/18/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1125482278
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,600.00 12/18/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1125482280
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $55.00 12/18/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1125482282
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $99.00 12/18/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1125482284
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $218.00 12/18/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1125482286
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $464.00 12/18/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1125482288
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $182.00 12/13/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1125482262
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,608.00 12/11/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1125482248
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $484.00 12/11/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1125482250
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,608.00 12/11/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1125482252
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $484.00 12/11/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1125482254
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,758.00 12/11/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1125482256
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $402.00 12/11/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1125482258
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,355.00 12/11/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1125482260
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $91.00 12/04/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1125482246
Principal investigator 1 Ferring International Pharmascience Center US $1,700.00 12/01/2024 Non-covered Recipient Entity
SOUTH ALABAMA MEDICAL SCIENCE FOUNDATION
A Randomized, Assessor-Blind, Parallel-Groups, Multicenter Trial Assessing the Safety and Efficacy, Including Pharmacokinetic Assessments, of CLENPIQ in Children Aged 2 Years to Less Than 9 Years No dispute reported 06/30/2026 1137461704
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,500.00 11/20/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1125482230
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,600.00 11/20/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1125482232
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $104.00 11/20/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1125482234
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $98.00 11/20/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1125482236
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $182.00 11/20/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1125482238
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $98.00 11/20/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1125482240
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $99.00 11/20/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1125482242
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $464.00 11/20/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1125482244
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $273.00 11/06/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1125482184
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $98.00 11/06/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1125482186
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $99.00 11/06/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1125482188
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $364.00 11/06/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1125482190
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,851.00 11/06/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1125482192
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $554.00 11/06/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1125482194
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $464.00 11/06/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1125482196
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $104.00 11/06/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1125482198
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $98.00 11/06/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1125482200
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $400.00 11/06/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1125482202
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $99.00 11/06/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1125482204
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,621.00 11/06/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1125482206
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,608.00 11/06/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1125482208
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $484.00 11/06/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1125482210
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,658.00 11/06/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1125482212
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,163.00 11/06/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1125482214
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,434.00 11/06/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1125482216
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $486.00 11/06/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1125482218
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,758.00 11/06/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1125482220
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $402.00 11/06/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1125482222
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,355.00 11/06/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1125482224
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $486.00 11/06/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1125482226
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $486.00 11/06/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1125482228
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $400.00 11/01/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1125482170
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $182.00 11/01/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1125482172
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $98.00 11/01/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1125482174
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,851.00 11/01/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1125482176
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $554.00 11/01/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1125482178
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $464.00 11/01/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1125482180
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,500.00 11/01/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1125482182
Principal investigator 1 QOL Medical, LLC $1,260.00 10/09/2024 Non-covered Recipient Entity
South Alabama Medical Science Foundation
QOL Pediatric Sucraid No dispute reported 06/30/2026 1142343765
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,621.00 10/09/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1125482164
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,658.00 10/09/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1125482166
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $484.00 10/09/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1125482168
Principal investigator 1 QOL Medical, LLC $3,920.00 10/03/2024 Non-covered Recipient Entity
South Alabama Medical Science Foundation
QOL Pediatric Sucraid No dispute reported 06/30/2026 1142343763
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $98.00 10/02/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1125482154
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $26.00 10/02/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1125482156
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $208.00 10/02/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1125482158
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $455.00 10/02/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1125482160
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $196.00 10/02/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1125482162
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $53.02 09/20/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1125482152
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $182.00 09/11/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1125482146
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,355.00 09/11/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1125482148
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,355.00 09/11/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1125482150
Principal investigator 1 QOL Medical, LLC $10,011.30 09/10/2024 Non-covered Recipient Entity
South Alabama Medical Science Foundation
QOL Pediatric Sucraid No dispute reported 06/30/2026 1142343773
Principal investigator 1 Ferring International Pharmascience Center US $1,000.00 09/01/2024 Non-covered Recipient Entity
SOUTH ALABAMA MEDICAL SCIENCE FOUNDATION
A Randomized, Assessor-Blind, Parallel-Groups, Multicenter Trial Assessing the Safety and Efficacy, Including Pharmacokinetic Assessments, of CLENPIQ in Children Aged 2 Years to Less Than 9 Years No dispute reported 06/30/2026 1137461643
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,851.00 08/14/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1125482132
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $400.00 08/14/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1125482134
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,970.00 08/14/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1125482136
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,970.00 08/14/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1125482138
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $400.00 08/14/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1125482140
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,355.00 08/14/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1125482142
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,908.00 08/14/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1125482144
Principal investigator 1 Ferring International Pharmascience Center US $3,755.30 08/08/2024 Non-covered Recipient Entity
SOUTH ALABAMA MEDICAL SCIENCE FOUNDATION
A Randomized, Assessor-Blind, Parallel-Groups, Multicenter Trial Assessing the Safety and Efficacy, Including Pharmacokinetic Assessments, of CLENPIQ in Children Aged 2 Years to Less Than 9 Years No dispute reported 06/30/2026 1137461612
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $196.00 08/02/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1125482124
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $554.00 08/02/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1125482126
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $99.00 08/02/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1125482128
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $928.00 08/02/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1125482130
Principal investigator 1 Ferring International Pharmascience Center US $400.00 08/01/2024 Non-covered Recipient Entity
SOUTH ALABAMA MEDICAL SCIENCE FOUNDATION
A Randomized, Assessor-Blind, Parallel-Groups, Multicenter Trial Assessing the Safety and Efficacy, Including Pharmacokinetic Assessments, of CLENPIQ in Children Aged 2 Years to Less Than 9 Years No dispute reported 06/30/2026 1137461606
Principal investigator 1 QOL Medical, LLC $6,689.20 07/19/2024 Non-covered Recipient Entity
South Alabama Medical Science Foundation
QOL Pediatric Sucraid No dispute reported 06/30/2026 1142343771
Principal investigator 1 Ferring International Pharmascience Center US $34,547.70 07/16/2024 Non-covered Recipient Entity
SOUTH ALABAMA MEDICAL SCIENCE FOUNDATION
A Randomized, Assessor-Blind, Parallel-Groups, Multicenter Trial Assessing the Safety and Efficacy, Including Pharmacokinetic Assessments, of CLENPIQ in Children Aged 2 Years to Less Than 9 Years No dispute reported 06/30/2026 1137461592
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $104.00 07/10/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1125482110
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $98.00 07/10/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1125482112
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $554.00 07/10/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1125482114
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $725.00 07/10/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1125482116
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $104.00 07/10/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1125482118
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $364.00 07/10/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1125482120
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $98.00 07/10/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1125482122
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,908.00 07/08/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1125482102
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $486.00 07/08/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1125482104
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,355.00 07/08/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1125482106
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,034.00 07/08/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1125482108
Principal investigator 1 Ferring International Pharmascience Center US $2,486.00 07/01/2024 Non-covered Recipient Entity
SOUTH ALABAMA MEDICAL SCIENCE FOUNDATION
A Randomized, Assessor-Blind, Parallel-Groups, Multicenter Trial Assessing the Safety and Efficacy, Including Pharmacokinetic Assessments, of CLENPIQ in Children Aged 2 Years to Less Than 9 Years No dispute reported 06/30/2026 1137461579
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $99.00 06/24/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1125482098
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $98.00 06/24/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1125482100
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,163.00 06/12/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1125482082
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,434.00 06/12/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1125482084
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,163.00 06/12/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1125482086
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,434.00 06/12/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1125482088
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $486.00 06/12/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1125482090
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,355.00 06/12/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1125482092
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $402.00 06/12/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1125482094
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,034.00 06/12/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1125482096
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $400.00 06/07/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1125482074
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $400.00 06/07/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1125482076
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $499.00 06/07/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1125482078
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,261.00 06/07/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1125482080
Principal investigator 1 Ferring International Pharmascience Center US $1,038.00 06/01/2024 Non-covered Recipient Entity
SOUTH ALABAMA MEDICAL SCIENCE FOUNDATION
A Randomized, Assessor-Blind, Parallel-Groups, Multicenter Trial Assessing the Safety and Efficacy, Including Pharmacokinetic Assessments, of CLENPIQ in Children Aged 2 Years to Less Than 9 Years No dispute reported 06/30/2026 1137461570
Principal investigator 1 Phathom Pharmaceuticals, Inc. $1,500.00 05/15/2024 Non-covered Recipient Entity
SOUTH ALABAMA MEDICAL SCIENCE
VPED-103 No dispute reported 06/30/2026 1151145011
Principal investigator 1 Phathom Pharmaceuticals, Inc. $500.00 05/15/2024 Non-covered Recipient Entity
SOUTH ALABAMA MEDICAL SCIENCE
VPED-103 No dispute reported 06/30/2026 1151145015
Principal investigator 1 Phathom Pharmaceuticals, Inc. $1,500.00 05/15/2024 Non-covered Recipient Entity
SOUTH ALABAMA MEDICAL SCIENCE
VPED-103 No dispute reported 06/30/2026 1151145019
Principal investigator 1 Phathom Pharmaceuticals, Inc. $2,000.00 05/10/2024 Non-covered Recipient Entity
SOUTH ALABAMA MEDICAL SCIENCE
VPED-103 No dispute reported 06/30/2026 1151144955
Principal investigator 1 QOL Medical, LLC $140.00 05/08/2024 Non-covered Recipient Entity
South Alabama Medical Science Foundation
QOL Pediatric Sucraid No dispute reported 06/30/2026 1142343759
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $50.00 05/08/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1125482072
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $400.00 05/03/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1125482070
Principal investigator 1 Ferring International Pharmascience Center US $3,500.00 05/01/2024 Non-covered Recipient Entity
SOUTH ALABAMA MEDICAL SCIENCE FOUNDATION
A Randomized, Assessor-Blind, Parallel-Groups, Multicenter Trial Assessing the Safety and Efficacy, Including Pharmacokinetic Assessments, of CLENPIQ in Children Aged 2 Years to Less Than 9 Years No dispute reported 06/30/2026 1137461553
Principal investigator 1 QOL Medical, LLC $800.00 03/28/2024 Non-covered Recipient Entity
South Alabama Medical Science Foundation
QOL Pediatric Sucraid No dispute reported 06/30/2026 1142343769
Principal investigator 1 Phathom Pharmaceuticals, Inc. $15,400.00 03/27/2024 Non-covered Recipient Entity
SOUTH ALABAMA MEDICAL SCIENCE
VPED-103 No dispute reported 06/30/2026 1151144903
Principal investigator 1 Phathom Pharmaceuticals, Inc. $1,500.00 03/27/2024 Non-covered Recipient Entity
SOUTH ALABAMA MEDICAL SCIENCE
VPED-103 No dispute reported 06/30/2026 1151144907
Principal investigator 1 Phathom Pharmaceuticals, Inc. $1,500.00 03/27/2024 Non-covered Recipient Entity
SOUTH ALABAMA MEDICAL SCIENCE
VPED-103 No dispute reported 06/30/2026 1151144912
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,719.00 03/13/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1125482068
Principal investigator 1 QOL Medical, LLC $3,412.10 03/11/2024 Non-covered Recipient Entity
South Alabama Medical Science Foundation
QOL Pediatric Sucraid No dispute reported 06/30/2026 1142343767
Principal investigator 1 Ferring International Pharmascience Center US $150.00 03/01/2024 Non-covered Recipient Entity
SOUTH ALABAMA MEDICAL SCIENCE FOUNDATION
A Randomized, Assessor-Blind, Parallel-Groups, Multicenter Trial Assessing the Safety and Efficacy, Including Pharmacokinetic Assessments, of CLENPIQ in Children Aged 2 Years to Less Than 9 Years No dispute reported 06/30/2026 1137461512
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $400.00 02/23/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1125482066
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $499.00 02/07/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1125482052
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $499.00 02/07/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1125482054
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $484.00 02/07/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1125482056
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,608.00 02/07/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1125482058
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,851.00 02/07/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1125482060
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $464.00 02/07/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1125482062
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $91.00 02/07/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1125482064
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $455.00 01/19/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1125482048
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $484.00 01/10/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1125482044
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,608.00 01/10/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1125482046
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $91.00 01/05/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1125482042
Principal investigator 1 QOL Medical, LLC $3,500.00 01/03/2024 Non-covered Recipient Entity
South Alabama Medical Science Foundation
QOL Pediatric Sucraid No dispute reported 06/30/2026 1142343761
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $800.00 01/03/2024 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1125482040